ERBB2 and non-small cell lung carcinoma: In HER2-overexpressing NSCLC, T-DXd use was associated with an ORR of 26.5% and 34.1% and median PFS of 5.7 months and 6.7 months in the cohorts receiving 6.4 mg/kg and 5.4 mg/kg, respectively [82] (Table 8).